Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Pancreatic Neoplasms HELP
Based on 32,387 articles published since 2008
|||| 50 

These are the 32387 published articles about Pancreatic Neoplasms that originated from Worldwide during 2008-2019.
 
+ Citations + Abstracts
Pages: 1 · 2 · 3 · 4 · 5 · 6 · 7 · 8 · 9 · 10 · 11 · 12 · 13 · 14 · 15 · 16 · 17 · 18 · 19 · 20
426 Editorial The prognosis for pancreatic cancer patients--better than feared. 2012

Buanes, Trond. · ·Tidsskr Nor Laegeforen · Pubmed #22240836.

ABSTRACT: -- No abstract --

427 Editorial What can we learn from Steve Jobs about complementary and alternative therapies? 2012

Greenlee, Heather / Ernst, Edzard. · ·Prev Med · Pubmed #22230682.

ABSTRACT: -- No abstract --

428 Editorial 18F-Labelled exendin to image GLP-1 receptor-expressing tissues: from niche to blockbuster? 2012

Boerman, Otto C / Gotthardt, Martin. · ·Eur J Nucl Med Mol Imaging · Pubmed #22170323.

ABSTRACT: -- No abstract --

429 Editorial Immunotherapy synergizes with chemotherapy targeting pancreatic cancer. 2012

Koido, Shigeo / Homma, Sadamu / Takahara, Akitaka / Namiki, Yoshihisa / Komita, Hideo / Uchiyama, Kan / Ito, Masaki / Gong, Jianlin / Ohkusa, Toshifumi / Tajiri, Hisao. · ·Immunotherapy · Pubmed #22149993.

ABSTRACT: -- No abstract --

430 Editorial Pancreatic cancer is not noble. 2012

Lotze, Michael T. · ·J Innate Immun · Pubmed #22086192.

ABSTRACT: -- No abstract --

431 Editorial Proteome-based biomarkers in pancreatic cancer. 2011

Sun, Chen / Rosendahl, Ann H / Ansari, Daniel / Andersson, Roland. · ·World J Gastroenterol · Pubmed #22171124.

ABSTRACT: Pancreatic cancer, as a highly malignant cancer and the fourth cause of cancer-related death in world, is characterized by dismal prognosis, due to rapid disease progression, highly invasive tumour phenotype, and resistance to chemotherapy. Despite significant advances in treatment of the disease during the past decade, the survival rate is little improved. A contributory factor to the poor outcome is the lack of appropriate sensitive and specific biomarkers for early diagnosis. Furthermore, biomarkers for targeting, directing and assessing therapeutic intervention, as well as for detection of residual or recurrent cancer are also needed. Thus, the identification of adequate biomarkers in pancreatic cancer is of extreme importance. Recently, accompanying the development of proteomic technology and devices, more and more potential biomarkers have appeared and are being reported. In this review, we provide an overview of the role of proteome-based biomarkers in pancreatic cancer, including tissue, serum, juice, urine and cell lines. We also discuss the possible mechanism and prospects in the future. That information hopefully might be helpful for further research in the field.

432 Editorial Pancreatic metastases from renal cell carcinoma: the state of the art. 2011

Ballarin, Roberto / Spaggiari, Mario / Cautero, Nicola / De Ruvo, Nicola / Montalti, Roberto / Longo, Cristina / Pecchi, Anna / Giacobazzi, Patrizia / De Marco, Giuseppina / D'Amico, Giuseppe / Gerunda, Giorgio Enrico / Di Benedetto, Fabrizio. · ·World J Gastroenterol · Pubmed #22147975.

ABSTRACT: Pancreatic metastases are rare, with a reported incidence varying from 1.6% to 11% in autopsy studies of patients with advanced malignancy. In clinical series, the frequency of pancreatic metastases ranges from 2% to 5% of all pancreatic malignant tumors. However, the pancreas is an elective site for metastases from carcinoma of the kidney and this peculiarity has been reported by several studies. The epidemiology, clinical presentation, and treatment of pancreatic metastases from renal cell carcinoma are known from single-institution case reports and literature reviews. There is currently very limited experience with the surgical resection of isolated pancreatic metastasis, and the role of surgery in the management of these patients has not been clearly defined. In fact, for many years pancreatic resections were associated with high rates of morbidity and mortality, and metastatic disease to the pancreas was considered to be a terminal-stage condition. More recently, a significant reduction in the operative risk following major pancreatic surgery has been demonstrated, thus extending the indication for these operations to patients with metastatic disease.

433 Editorial Targeting thrombosis in exocrine pancreas cancer: a continued need for improved therapies. 2011

Epstein, Andrew S / O'Reilly, Eileen M. · ·Expert Rev Anticancer Ther · Pubmed #22117145.

ABSTRACT: -- No abstract --

434 Editorial ¹⁸F-FDG PET/CT imaging of the pancreas: spectrum of diseases. 2011

Nguyen, Vien X / Nguyen, Cuong C / Nguyen, Ba D. ·Department of Gastroenterology and Hepatology, Mayo Clinic Arizona, Scottsdale, AZ 85259, USA. vnguy01@gmail.com ·JOP · Pubmed #22072244.

ABSTRACT: Since the introduction of integrated positron emission tomography-computed tomography (PET/CT), it has a great impact on the field of oncology. Comparing to other conventional scanners, only PET/CT is capable of providing important information on accurate detecting, staging/restaging, and post-therapeutic monitoring of many cancers. Many studies have demonstrated that PET/CT changes the management in approximately 30% of all cancer patients. Because 2-((18)F)-fluoro-2-deoxy-D-glucose (FDG) is a nonspecific tracer, understanding the PET/CT limitations and pitfalls for various pancreatic conditions can lead to more accurate interpretation of PET/CT images, which ultimately would impact patient care. As a result, it is important for radiologists and other clinicians to familiarize themselves with a wide spectrum of pancreatic PET/CT findings simulating cancer from benign entities.

435 Editorial Better imaging versus better value: striking a balance in confocal laser endomicroscopy. 2011

Hernandez, Lyndon V. · ·Gastrointest Endosc · Pubmed #22032313.

ABSTRACT: -- No abstract --

436 Editorial Outcomes when cancer treatment is delivered on, or off, a clinical trial: implications for generalizability of study results. 2011

Markman, Maurie. · ·Oncology · Pubmed #22024941.

ABSTRACT: -- No abstract --

437 Editorial What's new in oncologic pancreatic surgery. 2011

Ziparo, V / La Torre, M. · ·G Chir · Pubmed #22018213.

ABSTRACT: -- No abstract --

438 Editorial Locally advanced pancreatic cancer: where should we go from here? 2011

Philip, Philip Agop. · ·J Clin Oncol · Pubmed #21969514.

ABSTRACT: -- No abstract --

439 Editorial Significance of pathologic response to preoperative therapy in pancreatic cancer: the future ain't what it used to be. 2011

Allen, Peter J. · ·Ann Surg Oncol · Pubmed #21947699.

ABSTRACT: -- No abstract --

440 Editorial Pancreatic cancer in the UK. 2011

Anonymous3190705. · ·Lancet · Pubmed #21924981.

ABSTRACT: -- No abstract --

441 Editorial Everolimus and sunitinib: from mouse models to treatment of pancreatic neuroendocrine tumors. 2011

Liakakos, Theodore / Roukos, Dimitrios H. · ·Future Oncol · Pubmed #21919689.

ABSTRACT: -- No abstract --

442 Editorial New target therapies for patients with neuroendocrine tumors of the pancreas. 2011

Baltogiannis, Georgios / Katsios, Christos / Roukos, Dimitrios H. · ·Expert Rev Gastroenterol Hepatol · Pubmed #21910571.

ABSTRACT: -- No abstract --

443 Editorial Pain in pancreatic cancer: does drug treatment still play a role? 2011

Uomo, Ilaria. · ·JOP · Pubmed #21904067.

ABSTRACT: -- No abstract --

444 Editorial Use of predictive markers in oncology: are phase 3 trials always required? 2011

Markman, Maurie. · ·Oncology · Pubmed #21894048.

ABSTRACT: -- No abstract --

445 Editorial [Pancreatoduodenectomy--past, present and future]. 2011

Popescu, I / Dumitraşcu, T. · ·Chirurgia (Bucur) · Pubmed #21853734.

ABSTRACT: Pancreatico-duodenectomy represents one of the most important and complex surgical digestive procedure. Although rarely performed in the past, nowadays has become a routine surgery. Moreover, postoperative mortality significantly decreased (from over 30% to less than 5%), while the number of severe, life-threatening complications were reduced. This outcome was possible due to technical innovations acquired in time, and also due to a better per operative management of these patients, in tertiary surgical centers, with experienced operative teams. Some modifications of the standard procedure of resection, like posterior or artery first approach contributed to better results, facilitating en-block resection of the portal/ superior mesenteric vein, where needed. Moreover, posterior approach facilitates complete mesopancreas excision, involved in local recurrence after resection of pancreatic head adenocarcinoma. Regarding reconstruction after pancreaticoduodenectomy, there is no optimal type of anastomosis (pancreatico-gastrostomy vs pancreatico-jejunostomy), results being related mostly with the expertise of the operative team, as like the postoperative pancreatic fistula rate. Future studies are deemed to look on the real clinical impact of the total mesopancreas excision in achieving negative resection margins, decreasing local recurrence and increasing the long-term survival of patients resected for pancreatic head cancer.

446 Editorial Pancreatic neoplasm in 2011: an update. 2011

Saif, Muhammad Wasif. · ·JOP · Pubmed #21737886.

ABSTRACT: Pancreatic cancer still is a significant, unresolved therapeutic challenge with nearly similar incidence and mortality rates. It is the most lethal type of digestive cancer with a 5-year survival rate of 5%. Adjuvant chemotherapy remains to be gemcitabine alone or combined with infusional 5-fluorouracil with radiation therapy. Nevertheless, only a few patients survive for at least 5 years after R0 resection and adjuvant therapy. Most patients need palliative treatment. Once pancreatic cancer becomes metastatic, it is uniformly fatal with an overall survival of typically 6 months from diagnosis. Chemotherapy is an important component of palliative care but must be administered as a part of a multidisciplinary approach, including palliation of pain, managing weight loss, and deterioration in functional status. Gemcitabine has been the standard in both locally advanced and metastatic disease. The addition of the tyrosine kinase inhibitor erlotinib prolongs median survival for only 2 weeks. While gemcitabine-based regimens are currently accepted as the standard first-line treatment of patients with locally advanced or metastatic pancreatic adenocarcinoma, there is no consensus regarding treatment in the second-line setting. It will not be untrue to say that there are no real medical breakthroughs with regards to improving the prognosis of pancreatic cancer as of 2011. On the other hand, we have made some progress in patients with advanced pancreatic neuroendocrine tumors. These patients have a 5-year survival that can range from 97% in benign insulinomas to as low as 30% in non-functional metastatic pancreatic neuroendocrine tumors. Treatment options may include surgery, transarterial chemoembolization of liver metastases, and cytotoxic therapy such as streptozotocin, 5-fluorouracil or doxorubicin. Somatostatin analogues, like octreotide, have been proven to prolong progression-free survival in patients with metastatic neuroendocrine tumors of midgut origin. In 2011, two targeted agents, a tyrosine kinase inhibitor sunitinib and mTOR inhibitor everolimus have been approved by FDA for pancreatic neuroendocrine tumors. With these approvals, U.S. physicians can now offer their patients with progressive pancreatic neuroendocrine tumors. Patients with any stage of pancreatic cancer should be considered candidates for clinical trials.

447 Editorial GLP-1-based therapies: the dilemma of uncertainty. 2011

Spranger, Joachim / Gundert-Remy, Ursula / Stammschulte, Thomas. · ·Gastroenterology · Pubmed #21723985.

ABSTRACT: -- No abstract --

448 Editorial Rac1 takes center stage in pancreatic cancer and ulcerative colitis: quantity matters. 2011

Wertheimer, Eva / Kazanietz, Marcelo G. · ·Gastroenterology · Pubmed #21704620.

ABSTRACT: -- No abstract --

449 Editorial Pancreatic cancer prevention and the 2010 Dietary Guidelines for Americans. 2011

Harris, Diane M / Srihari, Priya / Go, Vay Liang W. · ·Pancreas · Pubmed #21673534.

ABSTRACT: -- No abstract --

450 Editorial Idiopathic recurrent pancreatitis: an EUS-based management approach. 2011

Papachristou, Georgios I / Topazian, Mark. · ·Gastrointest Endosc · Pubmed #21628013.

ABSTRACT: -- No abstract --

Back · Next